Wall Street analysts expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to report sales of $1.53 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for ZIOPHARM Oncology’s earnings. The highest sales estimate is $1.60 million and the lowest is $1.46 million. ZIOPHARM Oncology posted sales of $1.60 million during the same quarter last year, which would indicate a negative year over year growth rate of 4.4%. The firm is expected to announce its next earnings report on Monday, May 7th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full year sales of $1.53 million for the current year, with estimates ranging from $3.00 million to $6.40 million. For the next financial year, analysts forecast that the business will report sales of $6.40 million per share, with estimates ranging from $6.39 million to $6.40 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.59 million. The business’s revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.11) earnings per share.
ZIOP has been the topic of a number of recent research reports. Raymond James Financial restated a “hold” rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th. HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the stock a “buy” rating in a research report on Thursday, December 14th. ValuEngine lowered shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. BidaskClub upgraded shares of ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. Finally, Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Saturday, January 6th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $7.50.
ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.37 on Friday. The firm has a market cap of $620.38, a PE ratio of -8.09 and a beta of 1.42. ZIOPHARM Oncology has a 52-week low of $3.33 and a 52-week high of $7.88.
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in ZIOPHARM Oncology by 3.4% in the 4th quarter. BlackRock Inc. now owns 8,499,209 shares of the biotechnology company’s stock valued at $35,187,000 after purchasing an additional 280,003 shares during the last quarter. Geode Capital Management LLC boosted its holdings in ZIOPHARM Oncology by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 1,160,653 shares of the biotechnology company’s stock valued at $4,805,000 after purchasing an additional 22,575 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in ZIOPHARM Oncology by 4.2% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 644,642 shares of the biotechnology company’s stock valued at $2,669,000 after purchasing an additional 26,053 shares during the last quarter. Deutsche Bank AG boosted its holdings in ZIOPHARM Oncology by 141.1% in the 4th quarter. Deutsche Bank AG now owns 294,287 shares of the biotechnology company’s stock valued at $1,216,000 after purchasing an additional 172,227 shares during the last quarter. Finally, Vident Investment Advisory LLC boosted its holdings in ZIOPHARM Oncology by 38.8% in the 4th quarter. Vident Investment Advisory LLC now owns 293,082 shares of the biotechnology company’s stock valued at $1,213,000 after purchasing an additional 81,940 shares during the last quarter. Institutional investors own 40.19% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “ZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.53 Million” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://ledgergazette.com/2018/03/16/ziopharm-oncology-inc-ziop-expected-to-announce-quarterly-sales-of-1-53-million.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.